Episode Details

Pharma data sits under three rulebooks at once: GxP quality regulation, the FDA's 21 CFR Part 11 electronic records rule, and GDPR. The first two say keep everything and prove everything. The third says erase on request. This episode takes the position that the damage happens where they conflict, when a right to be forgotten workflow reaches into a Part 11 audit trail and makes it look modified to an inspector.

You come away able to audit your own deletion path, apply pseudonymization with a separately held key, use the GDPR research exemption by design, and argue why the chief data officer should own all three regimes. References include MIT Sloan Management Review and dbt Labs.

Key takeaways

• Trace your GDPR deletion workflow end to end and block it from touching any GxP or Part 11 audit trail.
• Delete the link between person and record, never the record itself.
• Use pseudonymization with the identity key stored separately and locked down so trial data stays intact.
• Design for the GDPR research exemption upfront rather than discovering it during an FDA inspection.
• Give one person, usually the chief data officer, authority across quality, privacy and records so no department owns the conflict alone.

Chapters
0:00 Three regimes pointing at one record
1:03 What GxP demands from the audit trail
1:54 GDPR erasure against permanent retention
2:39 How deletion scripts break Part 11 records
3:13 Pseudonymization and the GDPR research exemption
4:18 Who owns the conflict, and Monday's fix

Go deeper, free lessons

• GxP explained: the quality rulebook behind every batch of pills
• Global privacy regimes and what they mean for pharma data flows
• Running a data audit: from access logs to inspection readiness
• Consent, de-identification and the limits of anonymous data
• Building a pharma data governance operating model

Full article and transcript: https://www.mba-training.com/blog/gxp-21cfr-part11-gdpr-pharma-cdo

MBA Training, mba-training.com